Genetic Technologies Shares explode on new cancer risk assessment test
- Genetic Technologies (GTG) launches a new cancer risk assessment test designed to evaluate a woman’s risk of developing breast or ovarian cancer
- The “world-first” test combines GTG’s GeneType platform with other clinical risk factors to provide a risk assessment result from a single saliva sample
- GTG CEO Simon Morriss says the test means the company is moving beyond rare cancer-susceptibility genetics to address cancer risk at a population health level
- The company will first launch the new test in the US and showcase it at the BRCA 2023 Symposium in Montreal in early May
- Shares in GeneticTechnologies are up 167 per cent to 0.8 cents at 1:27 pm AEDT
